JP2004510426A5 - - Google Patents

Download PDF

Info

Publication number
JP2004510426A5
JP2004510426A5 JP2002532243A JP2002532243A JP2004510426A5 JP 2004510426 A5 JP2004510426 A5 JP 2004510426A5 JP 2002532243 A JP2002532243 A JP 2002532243A JP 2002532243 A JP2002532243 A JP 2002532243A JP 2004510426 A5 JP2004510426 A5 JP 2004510426A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002532243A
Other versions
JP2004510426A (ja
JP3908165B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/011428 external-priority patent/WO2002028419A2/en
Publication of JP2004510426A publication Critical patent/JP2004510426A/ja
Publication of JP2004510426A5 publication Critical patent/JP2004510426A5/ja
Application granted granted Critical
Publication of JP3908165B2 publication Critical patent/JP3908165B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002532243A 2000-10-04 2001-10-03 多発性硬化症の治療におけるケモカイン変異体 Expired - Fee Related JP3908165B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (3)

Publication Number Publication Date
JP2004510426A JP2004510426A (ja) 2004-04-08
JP2004510426A5 true JP2004510426A5 (ja) 2005-12-22
JP3908165B2 JP3908165B2 (ja) 2007-04-25

Family

ID=8170011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002532243A Expired - Fee Related JP3908165B2 (ja) 2000-10-04 2001-10-03 多発性硬化症の治療におけるケモカイン変異体

Country Status (31)

Country Link
US (1) US7402303B2 (ja)
EP (1) EP1326628B1 (ja)
JP (1) JP3908165B2 (ja)
KR (1) KR100837898B1 (ja)
CN (1) CN1285381C (ja)
AR (1) AR030854A1 (ja)
AT (1) ATE265222T1 (ja)
AU (2) AU1591902A (ja)
BG (1) BG66137B1 (ja)
BR (1) BR0114407A (ja)
CA (1) CA2423616C (ja)
CZ (1) CZ303409B6 (ja)
DE (1) DE60103078T2 (ja)
DK (1) DK1326628T3 (ja)
EA (1) EA006137B1 (ja)
EE (1) EE05174B1 (ja)
ES (1) ES2217199T3 (ja)
HK (1) HK1062811A1 (ja)
HR (1) HRP20030215B1 (ja)
HU (1) HUP0302194A3 (ja)
IL (2) IL155178A0 (ja)
MX (1) MXPA03003008A (ja)
NO (1) NO330278B1 (ja)
PL (1) PL204231B1 (ja)
PT (1) PT1326628E (ja)
RS (1) RS50738B (ja)
SI (1) SI1326628T1 (ja)
SK (1) SK287523B6 (ja)
UA (1) UA77950C2 (ja)
WO (1) WO2002028419A2 (ja)
ZA (1) ZA200302315B (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231057D1 (de) 2001-12-17 2009-03-19 Serono Lab Chemokine mutanten, die als chemokine antagonisten wirken
DK1494703T3 (da) 2002-04-04 2006-06-26 Applied Research Systems Chemokin-mutanter med forbedret oral biotilgængelighed
WO2004062688A2 (en) * 2002-12-23 2004-07-29 Applied Research Systems Ars Holding N.V. Use of cc-chemokine mutants against liver diseases
CA2534828A1 (en) * 2003-10-22 2005-05-06 Applied Research Systems Ars Holding N.V. Novel cxcl8 antagonists
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
SI1439191T1 (sl) * 2004-01-19 2006-06-30 Ares Trading Sa Postopek ciscenja proteinov izrazenih v bakteriji
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP1760110B1 (en) * 2005-09-03 2011-11-02 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
DK2185719T3 (en) 2007-08-02 2014-02-17 Novimmune Sa ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
AU2011213559B2 (en) * 2010-02-08 2015-05-07 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
CN112469430A (zh) 2018-05-28 2021-03-09 日内瓦大学 抑制大脑炎症的方法
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
AU2415599A (en) * 1997-12-23 1999-07-19 Fondazione Centro San Raffaele Del Monte Tabor Rantes mutants and therapeutic applications thereof
WO2000044408A2 (en) * 1999-01-29 2000-08-03 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists

Similar Documents

Publication Publication Date Title
BE2022C531I2 (ja)
BE2022C502I2 (ja)
BE2017C057I2 (ja)
BE2017C051I2 (ja)
BE2017C032I2 (ja)
BE2016C051I2 (ja)
BE2015C046I2 (ja)
BE2014C052I2 (ja)
BE2014C036I2 (ja)
BE2014C026I2 (ja)
BE2014C004I2 (ja)
BE2014C006I2 (ja)
BE2017C050I2 (ja)
BE2011C034I2 (ja)
BE2007C047I2 (ja)
AU2002307149A8 (ja)
JP2001318627A5 (ja)
CH1379220H1 (ja)
BRPI0204884A2 (ja)
BE2016C021I2 (ja)
BE2017C059I2 (ja)
BRPI0101486B8 (ja)
BE2012C051I2 (ja)
BRPI0210463A2 (ja)
AU2000280389A8 (ja)